Skip to main content
VIVOZON PHARMACEUTICAL CO., LTD. logo

VIVOZON PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 082800 ISIN · KR7082800004 KO Manufacturing
Open in API
Filings indexed 590 across all filing types
Latest filing 2021-07-19 Major Shareholding Noti…
Country KR South Korea
Listing KO 082800

About VIVOZON PHARMACEUTICAL CO., LTD.

https://www.vivozon.com/

VIVOZON PHARMACEUTICAL CO., LTD. is a research and development company specializing in the discovery and commercialization of innovative drugs, with a primary focus on pain and central nervous system (CNS) diseases. The company utilizes a multi-target drug development platform to create new chemical entities that act on multiple targets to achieve synergistic efficacy. This approach integrates efficacy-based screening from the early stages of discovery to identify candidate substances with a high potential for successful clinical development. Its lead pipeline candidate is Opiranserin (VVZ-149), a first-in-class, non-narcotic injectable analgesic for post-operative pain management. The company is actively expanding its pipeline to address a broader range of unmet medical needs within the CNS field.

Recent filings

Filing Released Lang Actions
[기재정정]최대주주변경
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system, specifically a 'Change in Largest Shareholder' (최대주주변경) report. It details the change in the company's controlling shareholder due to the exercise of convertible bonds. Since this is a specific regulatory disclosure regarding corporate ownership structure and does not fit into categories like M&A, Board changes, or financial reports, it is classified as a Regulatory Filing (RNS).
2021-07-19 Korean
[기재정정]주요사항보고서(전환사채권발행결정)
Share Issue/Capital Change Classification · 100% confidence The document is a formal 'Correction Report' (정정신고) regarding a previously filed 'Major Report' (주요사항보고서) concerning the issuance of convertible bonds (전환사채권 발행결정). It details specific changes to dates, interest payment methods, and redemption terms for the bonds. Since this is a regulatory filing detailing changes to a capital-raising instrument (convertible bonds) and is not a mere announcement of a report's availability, it falls under the category of Capital/Financing Update.
2021-07-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (DART system) used by corporate insiders to disclose changes in their shareholdings. This falls under the category of 'Director's Dealing' (DIRS) as it reports personal share transactions by company directors and major shareholders.
2021-06-07 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities (Financial Supervisory Service/Korea Exchange). It details the acquisition of shares by a major shareholder (Vivozon, Inc.) in the issuing company (Vivozon Healthcare). This type of filing is specifically categorized as a 'Director's Dealing' (DIRS) report, as it tracks insider/major shareholder transactions in the company's own securities.
2021-05-24 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed in South Korea. It details the acquisition of shares by a major shareholder (Vaultea, Inc.) and its special related parties (Vivozon, etc.) in the company 'Vivozon Healthcare'. This type of filing is specifically designed to notify the market when a shareholder crosses a significant ownership threshold (typically 5% or more). In the provided classification schema, this corresponds to a 'Major Shareholding Notification'.
2021-05-20 Korean
분기보고서 (2021.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the period ending March 31, 2021, submitted by Vivozon Healthcare. It contains detailed financial statements, management discussion, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2021
2021-05-17 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.